The Value of Biosimilars and Amgen's Commitment
Biosimilars have the potential to lower healthcare costs and bring savings to both patients and the healthcare system. Biosimilars increase competition in the marketplace, generally cost less to develop compared to originator biologics, and can potentially open opportunities for additional research and investment in new innovator products.
More Options for Patients
Biosimilars offer more treatment options for patients.1 With increased availability of biosimilars, patients have more options to choose the right medicine at the right time. The introduction of biosimilars promotes competition which can lead to additional savings to patients.
How Biosimilars Affect the Marketplace2-5
The competition fostered by a marketplace with biosimilars could benefit global healthcare systems
Opportunity for health system-wide cost savings
More treatment options for patients
Our Commitment
As a world leader and innovator in biologics for patients with life-threatening and chronic diseases, Amgen is proud to also produce biosimilar medicines in pursuit of its mission to serve patients.
Amgen's 9th Annual Biosimilar Trends Report
Since the first biosimilar entered the U.S. marketplace in 2015, biosimilars have gained significant share in the majority of therapeutic areas where they have been introduced. The U.S. marketplace is poised to see further growth in biosimilars approved to date, and welcome many new biosimilars in the years to come. Access our 2022 Biosimilars Trends Report here.
DOWNLOAD NOW
Interchangeable Biosimilars in the U.S.
The U.S. marketplace with biosimilars relies on scientifically robust regulatory standards to ensure product quality and efficacy, patient safety, and prescriber confidence. One critical component of these standards is the interchangeability designation. Discover what the interchangeability designation means in the U.S. with this helpful fact sheet.
DOWNLOAD NOWReferences:
- The Center For Biosimilars. Biosimilars market is ripe for cost savings. www.centerforbiosimilars.com/contributor/chad- pettit/2019/06/biosimilars-market-is-ripe-for-cost-savings. Accessed January 1, 2024.
- Dolinar RO. Biosimilars are not generics. Endocrine Today. www.healio.com/endocrinology/practice-management/ news/print/endocrinetoday/%7Bfd6accbd-a927-467b-ba5e-4f8796327816%7D/biosimilars-are-not-generics. Accessed January 1, 2024.
- Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition. www.ftc.gov/os/2009/06/ P083901biologicsreport.pdf. Accessed January 1, 2024.
- U.S. Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018.
- The Biosimilars Council. Biosimilars in the United States. http://biosimilarscouncil.org/wp-content/uploads/2019/03/ Biosimilars-Council-Patient-Access-Study.pdf. Accessed January 1, 2024.